口服选择性雌激素受体降解剂抗乳腺癌新药艾拉司群
Oral selective estrogen receptor depressant,the new anti-breast cancer drug elacestrant
曾凡新 1王柯厶2
作者信息
- 1. 重庆城市管理职业学院智慧康养学院,重庆 401331
- 2. 重庆医药高等专科学校药学院,重庆 401331
- 折叠
摘要
选择性雌激素受体降解剂(selective estrogen receptor degrader,SERD)是雌激素受体(estrogen receptor,ER)阳性的晚期乳腺癌(breast cancer)内分泌治疗的常用药物.艾拉司群(elacestrant)是治疗晚期乳腺癌ER阳性,人表皮细胞生长因子受体(human epidermal growth factor receptor,HER)2阴性的新型口服SERD,疗效优于其他内分泌治疗,可显著改善患者中位无进展生存期,且对于ER基因α突变的乳腺癌患者有效.艾拉司群的上市将为ER阳性、HER2阴性的晚期乳腺癌患者提供更有效的治疗药物选择.
Abstract
Selective estrogen receptor degrader(SERD)is commonly used in the endocrine therapy of estrogen receptor(ER)positive advanced breast cancer.Elacestrant is a novel oral SERD that is for the treatment of advanced breast cancer with ER-positive and human epidermal growth factor receptor(HER)2-negative.It is more effective than other endocrine therapies and can significantly improve the median progression free survival of patients,and is also effective for breast cancer patients with ER gene α mutations.The launch of elacestrant will provide a more effective treatment option for patients with ER-positive,HER2-negative advanced breast cancer.
关键词
选择性雌激素受体降解剂/乳腺癌/艾拉司群/临床疗效/安全性Key words
selective estrogen receptor degrader/breast cancer/elacestrant/clinical efficacy/safety引用本文复制引用
基金项目
2022年重庆城市管理职业学院高层次人才科研启动基金项目(2022KYQD03)
出版年
2024
NETL
NSTL
万方数据